SNM (also known as sacral nerve stimulation) therapy is delivered by a stimulator implanted subcutaneously in the upper buttock. The stimulator generates electric pulses. Lead electrodes implanted through corresponding sacral foramen transmit these pulses from the stimulator to the sacral nerves. NICE is currently working to respond to the operational challenges posed to our normal work programmes. The stakeholders and advisory committees involved in the development of our guidance include a large number of frontline NHS staff. We know that their priority in this crisis is caring for patients and we do not want to draw them away from this vital work. For this reason, we are reviewing all of our guidance in development and will be prioritising only therapeutically critical topics at this time. Please accept our apologies for any disappointment this may cause. This is a rapidly changing situation and we will keep our approach under review. Our priority is to support the NHS to care for people during this difficult time. At present we’re not able to confirm the key dates for this guidance topic.
 
Status In progress
Process MT
ID number 417

Provisional Schedule

Resolution 20 April 2020
Expected publication 01 June 2020

Project Team

Project lead Tosin Oladapo

Email enquiries

Stakeholders

External assessment group Cedar
Manufacturers Axonics Modulation Technologies
Professional groups Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  British Society of Urogynaecology
  British Association of Urological Surgeons

Timeline

Key events during the development of the guidance:

Date Update
20 March 2020 Committee meeting: 2
14 February 2020 - 13 March 2020 Draft guidance: 1
24 January 2020 Committee meeting: 1
20 August 2019 Scope published
10 July 2019 Stakeholder registration opens

For further information on how we develop guidance, please see our page about NICE medical technologies guidance